Caseware UK (AP4) 2024.0.164 2024.0.164 2025-01-312025-01-31falseNo description of principal activity2024-02-01false11truetrueThe members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006. 09941651 2024-02-01 2025-01-31 09941651 2023-02-01 2024-01-31 09941651 2025-01-31 09941651 2024-01-31 09941651 c:Director1 2024-02-01 2025-01-31 09941651 d:CurrentFinancialInstruments 2025-01-31 09941651 d:CurrentFinancialInstruments 2024-01-31 09941651 d:CurrentFinancialInstruments d:WithinOneYear 2025-01-31 09941651 d:CurrentFinancialInstruments d:WithinOneYear 2024-01-31 09941651 d:ShareCapital 2025-01-31 09941651 d:ShareCapital 2024-01-31 09941651 d:RetainedEarningsAccumulatedLosses 2025-01-31 09941651 d:RetainedEarningsAccumulatedLosses 2024-01-31 09941651 c:FRS102 2024-02-01 2025-01-31 09941651 c:AuditExempt-NoAccountantsReport 2024-02-01 2025-01-31 09941651 c:FullAccounts 2024-02-01 2025-01-31 09941651 c:PrivateLimitedCompanyLtd 2024-02-01 2025-01-31 09941651 2 2024-02-01 2025-01-31 09941651 e:PoundSterling 2024-02-01 2025-01-31 iso4217:GBP xbrli:pure

Registered number: 09941651










PEDEN BLOODSTOCK GMBH LIMITED








UNAUDITED

FINANCIAL STATEMENTS

INFORMATION FOR FILING WITH THE REGISTRAR

FOR THE YEAR ENDED 31 JANUARY 2025

 
PEDEN BLOODSTOCK GMBH LIMITED
REGISTERED NUMBER: 09941651

STATEMENT OF FINANCIAL POSITION
AS AT 31 JANUARY 2025

2025
2024
Note
£
£

  

Current assets
  

Debtors: amounts falling due within one year
 4 
70,000
5,113

Bank and cash balances
  
376,012
437,902

  
446,012
443,015

Creditors: amounts falling due within one year
 5 
(98,576)
(209,770)

Net current assets
  
 
 
347,436
 
 
233,245

Total assets less current liabilities
  
347,436
233,245

  

Net assets
  
347,436
233,245


Capital and reserves
  

Called up share capital 
  
100
100

Profit and loss account
  
347,336
233,145

  
347,436
233,245


Page 1

 
PEDEN BLOODSTOCK GMBH LIMITED
REGISTERED NUMBER: 09941651
    
STATEMENT OF FINANCIAL POSITION (CONTINUED)
AS AT 31 JANUARY 2025

The director considers that the Company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the Company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006.

The director acknowledges her responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the statement of income and retained earnings in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf by: 






F McCormack
Director

Date: 29 October 2025

The notes on pages 3 to 5 form part of these financial statements.

Page 2

 
PEDEN BLOODSTOCK GMBH LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 JANUARY 2025

1.


General information

The company Peden Bloodstock GMBH Limited (09941651) is a privately owned limited company in England and Wales. The registered office address is West Grange, Harmby, Leyburn, North Yorkshire, DL8 5HQ.

2.Accounting policies

 
2.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with Section 1A of Financial Reporting Standard 102, the Financial Reporting Standard applicable in the UK and the Republic of Ireland and the Companies Act 2006.

The following principal accounting policies have been applied:

 
2.2

Revenue

Revenue is recognised to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured. Revenue is measured as the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. The following criteria must also be met before revenue is recognised:

Rendering of services

Revenue from a contract to provide services is recognised in the period in which the services are provided in accordance with the stage of completion of the contract when all of the following conditions are satisfied:
the amount of revenue can be measured reliably;
it is probable that the Company will receive the consideration due under the contract;
the stage of completion of the contract at the end of the reporting period can be measured reliably; and
the costs incurred and the costs to complete the contract can be measured reliably.

 
2.3

Debtors

Short-term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

 
2.4

Interest income

Interest income is recognised in the Statement of income and retained earnings using the effective interest method.

 
2.5

Cash and cash equivalents

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

Page 3

 
PEDEN BLOODSTOCK GMBH LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 JANUARY 2025

2.Accounting policies (continued)

 
2.6

Creditors

Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

 
2.7

Dividends

Equity dividends are recognised when they become legally payable. Interim equity dividends are recognised when paid. Final equity dividends are recognised when approved by the shareholders at an annual general meeting.

 
2.8

Foreign currency translation

Functional and presentation currency

The Company's functional and presentational currency is GBP.

Transactions and balances

Foreign currency transactions are translated into the functional currency using the spot exchange rates at the dates of the transactions.

At each period end foreign currency monetary items are translated using the closing rate. Non-monetary items measured at historical cost are translated using the exchange rate at the date of the transaction and non-monetary items measured at fair value are measured using the exchange rate when fair value was determined.

 
2.9

Taxation

Tax is recognised in profit or loss except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the Company operates and generates income.


3.


Employees

The average monthly number of employees, including directors, during the year was 1 (2024 - 1).

Page 4

 
PEDEN BLOODSTOCK GMBH LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 JANUARY 2025

4.


Debtors

2025
2024
£
£


Trade debtors
70,000
-

Prepayments and accrued income
-
5,113

70,000
5,113



5.


Creditors: Amounts falling due within one year

2025
2024
£
£

Corporation tax
89,699
58,285

Other creditors
5,891
149,186

Accruals and deferred income
2,986
2,299

98,576
209,770


 
Page 5